Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| FULC | SC 13G/A | neutral | 3/10 | BlackRock Portfolio Management LLC filed an amended Schedule 13G disclosing a 8.1% passive stake in Fulcrum Therapeutics | Oct 27, 2026 |
| DWTX | SC 13D/A | neutral | 3/10 | Sealbond Ltd, the controlling shareholder of Dogwood Therapeutics, filed Amendment No. 4 to its Schedule 13D, reporting | Oct 27, 2026 |
| NRC | 8-K | neutral | 5/10 | NRC Health reported Q3 2026 revenue of $38.4M, up 11% YoY, and GAAP/Adjusted EPS of $0.21, in line with the consensus es | Oct 27, 2026 |
| SGMOQ | 8-K | bullish | 7/10 | Sangamo Therapeutics filed amended monthly operating reports for July and August 2026, and its initial September 2026 mo | Oct 27, 2026 |
| WVE | SC 13G/A | neutral | 2/10 | BlackRock filed an amended Schedule 13G reporting a passive stake in Wave Life Sciences as of September 30, 2026. The fi | Oct 27, 2026 |
| SUPN | COURT-RULING | bearish | 5/10 | The Delaware Superior Court issued a post-summary-judgment ruling in US WorldMeds v. Supernus Pharmaceuticals, awarding | Oct 27, 2026 |
| OWPC | 8-K | neutral | 3/10 | One World Products announced a strategic investment and commercial partnership with Los Gatos Tomato Products to develop | Oct 27, 2026 |
| AMGN | INST-CLUSTER | mixed | 3/10 | Institutional activity in AMGN during Q3 2026 was mixed: two asset managers added $429.4M in holdings (led by Assenagon | Oct 27, 2026 |
| HELP | 6-K | neutral | 3/10 | Helus Pharma announced that co-founders Eric So and Paul Glavine have stepped down from executive and consulting roles b | Oct 27, 2026 |
| MEDP | 144 | neutral | 2/10 | Susan E. Burwig, an officer of Medpace Holdings, Inc., filed a Form 144 notice of intent to sell 3,940 shares of common | Oct 27, 2026 |
| ONCY | 8-K | bullish | 6/10 | Oncolytics Biotech announced updated data from Cohort 4 of the GOBLET study showing a median duration of response of app | Oct 27, 2026 |
| ONCY | PRESS-RELEASE | bullish | 6/10 | Oncolytics Biotech announced updated data from Cohort 4 of its Phase 1/2 GOBLET study showing a median duration of respo | Oct 27, 2026 |
| MRNA | ANALYST-DOWNGRADE | bearish | 4/10 | William Blair double-downgraded Moderna (MRNA) from Outperform to Market Perform on October 27, 2026, with no price targ | Oct 27, 2026 |
| GOVX | 8-K | bearish | 6/10 | GeoVax Labs entered into a $1 million unsecured revolving loan agreement with Bowery Consulting Group, with draws at the | Oct 27, 2026 |
| RNA | 8-K | neutral | 3/10 | Atrium Therapeutics announced the first patient has been dosed in its Phase 1/2 Corventis clinical trial evaluating ATR | Oct 27, 2026 |
| PYXS | PRESS-RELEASE | neutral | 4/10 | Pyxis Oncology announced a late-breaking oral presentation of Phase 1 data for its lead ADC, micvotabart pelidotin (MICV | Oct 27, 2026 |
| ABT | ANALYST-DOWNGRADE | neutral | 2/10 | Argus Research double-downgraded Abbott Laboratories (ABT) from Buy to Hold on October 27, 2026, a contrarian call again | Oct 27, 2026 |
| ONCO | 425 | neutral | 3/10 | Onconetix filed this 425 to announce that its acquisition target Realbotix launched the Echo humanoid robot line, with a | Oct 27, 2026 |
| ONCO | PRESS-RELEASE | neutral | 3/10 | Onconetix issued a press release summarizing Realbotix's launch of the Echo humanoid robot platform, priced at $11,950 ( | Oct 27, 2026 |
| ARTV | 8-K | bearish | 6/10 | Artiva Biotherapeutics is discontinuing all development of its sole pipeline candidate AlloNK (AB-101) after updated lon | Oct 27, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine announced completion of patient recruitment for the first cohort (80 mg, 6 patients) of Part B of its | Oct 27, 2026 |
| CMND | PRESS-RELEASE | neutral | 4/10 | Clearmind Medicine completed patient recruitment for the first segment of Part B of its Phase I/IIa trial of CMND-100 in | Oct 27, 2026 |
| ALT | 8-K | neutral | 3/10 | Altimmune appointed Peter Greenleaf and Alex Howarth to its board of directors, effective November 2, 2026, and increase | Oct 27, 2026 |
| CDT | 8-K | bearish | 6/10 | CDT entered an evaluation agreement with Manoira Corporation to assess its clinical-stage compounds AZD1656 and AZD5904 | Oct 27, 2026 |
| SXTP | PRESS-RELEASE | bullish | 6/10 | 60 Degrees Pharmaceuticals reported positive clinical and molecular results from the first five patients to complete tre | Oct 27, 2026 |
| SXTP | 8-K | neutral | 5/10 | 60 Degrees Pharmaceuticals announced positive results from its expanded access study of tafenoquine combination regimens | Oct 27, 2026 |
| ENLV | 6-K | bearish | 6/10 | Enlivex received a Nasdaq delisting notice for failing the $1.00 minimum bid price requirement over 30 consecutive busin | Oct 27, 2026 |
| ENTX | 8-K | neutral | 3/10 | Entera Bio appointed Dr. Juan Camilo Arjona Ferreira, Head of R&D and CMO at Organon, to its Board of Directors effectiv | Oct 27, 2026 |
| IMRN | 6-K | neutral | 4/10 | Immuron reported Q1 FY27 global sales of AUD$2.2 million, up 9% year-over-year and 5% sequentially, driven by strong Aus | Oct 27, 2026 |
| RADX | 6-K | neutral | 3/10 | Radiopharm Theranostics filed its Notice of Annual General Meeting and proxy form via a 6-K. The AGM will be held virtua | Oct 27, 2026 |